Stanford researchers have engineered retroviral and virus-like delivery systems for producing universal pseudotyped vehicles for cell and gene therapies.
Stanford scientists have developed a strategy that enables simultaneous and combinatorial genetic screening across different types of genetic perturbations (gene knockouts, knock-ins, overexpression, and gene domain modification).
Stanford researchers have developed a strategy for engineering next-generation cell therapies where gene knock-in is tightly coupled to gene knockout, preventing dangerous side effects associated with cells that have the knockout in the absence of the knock-in and vice versa.
A team of Stanford researchers has identified a group of small molecules that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Researchers at Stanford, led by Prof. Crystal Mackall and Prof. Jennifer R Cochran, have developed a unique approach to cancer treatment by tackling both the innate and adaptive immune systems.
Stanford researchers have developed a new phospho-responsive system to control protein secretion and surface expression of any tagged protein of interest. The invention enables complex control of multiple proteins.
A Stanford research team has patented methods that can prevent or reverse T cell exhaustion, thereby increasing the effectiveness of adoptive T cell therapies to fight cancer or chronic infections.
Stanford researchers have developed a strategy for generating chimeric transcription factors that enables exhaustion-resistant CAR-T cells and can be generalized to a wide range of cell therapies.
Researchers at Stanford have harnessed nanoprobes to longitudinally track immune system activation at a single-cell level, in response to immunotherapies.
Researchers at Stanford have developed a method of culture media supplementation with inosine during the chimeric antigen receptor (CAR)-T cell manufacturing process which can alter and enhance CAR-T cell metabolism and anti-tumor functions.
Stanford researchers in the Wu Lab have developed hypoallergenic and immunogenic induced pluripotent stem cells that could be used as a cancer treatment or prophylactic.
One of the main shortcomings of the clinical use of Hematopoietic Stem Cells (HSCs) is the limited number of cells that can be safely harvested from a patient.